Allarity Therapeutics Enrolls First Patient in Phase 2 Trial of Stenoparib for Advanced Ovarian Cancer

Allarity Therapeutics (ALLR) has enrolled the first patient in its Phase 2 clinical trial of stenoparib, a dual PARP and WNT pathway inhibitor, for advanced, platinum-resistant or platinum-ineligible ovarian cancer. The trial, building on previous promising data, aims to optimize dosing and assess stenoparib's impact on the WNT signaling pathway, with significant data expected by late summer 2026. This trial is part of Allarity's strategy to secure FDA approval for stenoparib and its companion diagnostic, the Drug Response Predictor (DRP®), to identify patients most likely to benefit from the treatment.

Analysis

Allarity Therapeutics (NASDAQ: ALLR) has initiated a new Phase 2 clinical trial for stenoparib—a dual PARP and WNT pathway inhibitor for which Allarity holds exclusive global development and commercialization rights and was originally developed by Eisai Co. Ltd.—by enrolling the first patient. The trial targets advanced, platinum-resistant or platinum-ineligible ovarian cancer, an area with significant unmet medical need. This study builds upon prior encouraging data where stenoparib demonstrated durable clinical benefit, with some patients showing positive outcomes for over 20 months, and was well-tolerated. The new protocol, reflecting input from gynecologic oncologists, aims to optimize dosing strategies in alignment with the FDA's Project Optimus initiative, confirm benefits of twice-daily dosing, and further investigate stenoparib's modulation of the WNT signaling pathway, a key driver in cancer progression, with significant clinical data anticipated by late summer 2026. A crucial component of Allarity's strategy is the concurrent development and pursuit of FDA approval for stenoparib alongside its Drug Response Predictor (DRP®) companion diagnostic, designed to identify patients most likely to benefit from the therapy based on gene expression signatures. While this development signals progress and carries a "moderately positive" sentiment (overall sentiment score 0.5, ALLR-specific sentiment 0.8), inherent risks include potential for trial results not meeting expectations, patient enrollment delays, and the critical need for the DRP® companion diagnostic to be validated and approved to realize stenoparib's full market potential.

Key Decisions for Investors

• Investors should monitor Allarity's progress in the Phase 2 trial for stenoparib, particularly enrollment pace, interim data on dosing optimization, and WNT pathway modulation insights, ahead of the significant data readout expected by late summer 2026.
• The validation and potential FDA approval of the Drug Response Predictor (DRP®) companion diagnostic is a critical catalyst; its success is pivotal for stenoparib's targeted efficacy and market adoption, warranting close observation.
• Given Allarity is a clinical-stage biopharmaceutical company, investment considerations should account for the long-term horizon until potential commercialization and the inherent risks associated with clinical trial outcomes and regulatory approvals, despite the positive step of trial initiation.